Results 251 to 260 of about 172,155 (289)

P13

Oral Diseases, 2005
Withdrawn/transferred ...
openaire   +1 more source

P13

Surgery for Obesity and Related Diseases, 2007
Olga Tucker, Nahum Beglaibter, Raul J. Rosenthal   +2 more
  +4 more sources

Biodegradation of Pendimethalin by Paracoccus sp. P13

Current Microbiology, 2018
In this study, a bacterial strain P13 capable of degrading pendimethalin was isolated from the soil of a fruit garden. Based on observed cellular morphology and physiology characteristics and a phylogenetic analysis of 16S rRNA gene sequences, strain P13 was identified as a member of the genus Paracoccus.
Haiyan, Ni, Na, Li, Jiguo, Qiu, Qing, Chen, Jian, He   +4 more
openaire   +2 more sources

P13

Surgery for Obesity and Related Diseases, 2006
Stephanie F. Yeager, Christopher D. Still, Peter Benotti, Anthony Petrick, William Strodel, Shawn Yoder, Craig Wood   +6 more
openaire   +2 more sources

Kolofon P13

Peripeti
Peripeti eti og for fatterne   TEMAREDAKTION Janicke Branth, Birgitte Hesselaa, Mia Rendix og Mads Thygesen. REDAKTION Erik Exe Christoffersen (ansv.), Janicke Branth, Falk Heinrich, Mads Thygesen, Thomas Rosendal Nielsen, Birgitte Hesselaa, Laura Schultz, Solveig Gade, Michael Eigrved, Jens Christian Lauenstein Led, Thomas David Kragebæk ...
openaire   +1 more source

A Review of CT-P13: An Infliximab Biosimilar

BioDrugs, 2014
CT-P13 (Remsima™; Inflectra™), a biosimilar of reference infliximab (Remicade(®)), is approved by the European Medicines Agency for use in all indications for which reference infliximab is approved, including rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriatic arthritis and psoriasis.
openaire   +2 more sources

CT-P13 in the treatment of rheumatoid arthritis

Expert Review of Clinical Immunology, 2017
The first biosimilar infliximab, CT-P13 infliximab-dyyb was approved in 2013 by the European Medicines Agency (EMA) and in 2016 by the United States Food and Drug Administration (FDA) and has been used for the treatment of rheumatoid arthritis (RA) for 4 years.
openaire   +2 more sources

Abstract P13

Plastic and Reconstructive Surgery, 2014
Gaby Doumit, Frank Papay, Michael Yaremchuk, James Zins   +3 more
openaire   +2 more sources

Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness

Advances in Therapy, 2021
Jae-Hee Cheon, Hyoun Woo Kang, Yun-Jeong Lim   +2 more
exaly  

P13

Cryobiology, 2014
John M. Baust, Daniel P. Klossner, Anthony Robilotto, Robert G. Van Buskirk, Andrew A. Gage, Thomas J. Polascik, John G. Baust   +6 more
openaire   +1 more source